Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAA604
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
AAA604 (also known as 177Lu-FF58) is an investigational radioligand therapy developed by Novartis in collaboration with PeptiDream. It consists of FF58, a non-RGD small molecule targeting the transmembrane integrin receptors αvβ3 and αvβ5, conjugated to the beta-emitting radioisotope lutetium-177 (177Lu). AAA604 was evaluated in a Phase 1 clinical trial for the treatment of advanced solid tumors, including pancreatic ductal adenocarcinoma, gastroesophageal adenocarcinoma, and glioblastoma multiforme. In December 2024, Novartis terminated the Phase 1 trial, and in August 2025, PeptiDream confirmed that development of the FF58 program would not be continued.
- Other names
- 177Lu-FF58Lu-FF58Lu-FF-58Lu-FF 58[177Lu]Lu-FF58lutetium (177Lu) FF58lutetium Lu 177 FF58
02
Targets
αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)
Beyond the preview
Go deeper on AAA604.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAA604.